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Background. Recent approaches have sought to harness the potential of stem cells to regenerate bone that is lost as
a consequence of trauma or disease. Bone marrow aspirate (BMA) provides an autologous source of osteoprogenitors for
such applications. However, previous studies indicated that the concentration of osteoprogenitors present in BMA is less
than required for robust bone regeneration. We provide further evidence for the importance of BMA enrichment for skeletal
tissue engineering strategies using a novel acoustic wave-facilitated ﬁltration strategy to concentrate BMA for osteoproge-
nitors, clinically applicable for intraoperative orthopedic use. Methods. Femoral BMA from 15 patients of an elderly cohort
was concentrated for the nucleated cell fraction against erythrocytes and excess plasma volume via size exclusion ﬁltration
facilitated by acoustic agitation. The effect of aspirate concentration was assessed by assays for colony formation, ﬂow
cytometry, multilineage differentiation and scaffold seeding efﬁciency. Results. BMA was ﬁltered to achieve a mean 4.2-fold
reduction in volume with a corresponding enrichment of viable and functional osteoprogenitors, indicated by ﬂow cytometry
and assays for colony formation. Enhanced osteogenic and chondrogenic differentiation was observed using concentrated
aspirate and enhanced cell-seeding efﬁciency onto allogeneic bone graft as an effect of osteoprogenitor concentration relative
speciﬁcally to the concentration of erythrocytes in the aspirate. Conclusions. These studies provide evidence for the impor-
tance of BMA nucleated cell concentration for both cell differentiation and cell seeding efﬁciency and demonstrate the
potential of this approach for intraoperative application to enhance bone healing.
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Tissue engineering strategies seek to harness the
regenerative potential of stem or progenitor cells to
replace tissue lost or damaged through injury or
disease. In orthopedics, applications may include
arthritides, spinal fusion, tendinopathies and bone
stock replacement after trauma, after excision of
neoplastic or infected bone, or for revision arthro-
plasty (1e3). Aspirated bone marrow possesses
considerable potential in such applications as an
autologous source of osteoprogenitors able to
regenerate bone and cartilage tissue. Although
connective tissue progenitors are resident in many
tissues, bone marrow serves as the richest and most
readily available repository of progenitor cells
capable of differentiating into mature bone-forming*These authors contributed equally to this work.
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http://dx.doi.org/10.1016/j.jcyt.2012.09.004cells (4); much of the osteogenic capacity of autol-
ogous bone graft derives from the bone marrow
component (5).
However, despite some notable isolated successes
in which the regenerative capacity of autologous
bone marrow aspirate (BMA) has been successfully
applied in the treatment of chronic wounds (6) and
in combination with demineralized bone matrix for
the treatment of aneurysmal (7) and unicameral (8)
bone cysts, variable results obtained with aspirated
cells suggest that concentration of BMA for osteo-
progenitor cells may be required to sustain robust
skeletal regeneration (9e12). The proportion of
osteoprogenitors present in bone marrow is typically
only approximately 0.005% of total nucleated cells
(NCs), and these numbers are variable, dependentp, Centre for Human Development, Stem Cells & Regeneration, Institute of
United Kingdom. E-mail: roco@soton.ac.uk
ublished by Elsevier Inc. Open access under CC BY license.
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Although this low cell concentration is sufﬁcient
when transplanting bulk autograft bone, where cells
are translocated within their existing osteoinductive
environment (and supplemented by osteoprogenitors
present within the bone matrix (17,18)), robust
skeletal regeneration using aspirated bone marrow
appears likely to require pre-emptive cellular en-
richment (19e21).
Key clinical and pre-clinical studies have estab-
lished the importance of osteoprogenitor concentra-
tion and number on bone repair. Early clinical and
pre-clinical studies by Connolly et al. (10,22) indi-
cated that the NC concentration of BMA was signiﬁ-
cant for bone formation and repair. More recently,
Hernigou et al. (23) successfully treated 53 of 60
patients with femoral head osteonecrosis or fracture
non-unions via percutaneous injection of BMA con-
centrated for osteoprogenitors. Retrospective analysis
of osteoprogenitor number (by colony-forming unit-
ﬁbroblastoid [CFU-F] analysis) revealed that the
seven atrophic non-unions that failed to heal had
signiﬁcantly lower numbers and concentration of
osteoprogenitors.
In the current study, we demonstrate the poten-
tial to concentrate, via ﬁltration, the nucleated frac-
tion of bone marrow aspirate obtained from
a clinically relevant elderly cohort and provide in vitro
evidence that may account for the signiﬁcance
osteoprogenitor concentration possesses for the
regenerative efﬁcacy of BMA. Adopting an approach
to cell ﬁltration applicable within the sterile ﬁeld of
an operating room (24), we demonstrate the ability
to process and enrich BMA efﬁciently for osteopro-
genitors and the signiﬁcance of cell concentration for
osteogenic and chondrogenic cell differentiation and
seeding efﬁciency onto allogeneic bone graft.Methods
Patient selection
Volunteers were selected from hematologically normal
patients undergoing primary total hip replacement
for symptomatic osteoarthritis. Exclusion criteria were
pre-existing conditions that may have confounding
effects on cellular activity, including a history of
Paget’s disease of bone, malignancy, clotting dis-
orders, osteogenesis imperfecta, rheumatoid arthritis,
osteonecrosis of the femoral head, long-term bis-
phosphonate or glucocorticoid therapy and known
transmissible disease (e.g., hepatitis, human immuno-
deﬁciency virus, malaria) or sickle cell disease. Patients
provided fully informed consent after receiving a lay
summary of the trial, together with a verbal explanation
and an opportunity for questioning. Ethical approvalof the study was obtained locally (LREC194/99/1) and
regionally (Research Ethics Committee 09/H0505/5).
MHRA (Medicines and Healthcare products Regula-
tory Agency) registration was unnecessary at this stage
because the device was not being used for direct ther-
apeutic intervention.Bone marrow harvest from the femoral canal
BMA for in vitro experimentation was harvested as
waste tissue from the femoral canal during total
hip replacement surgery. Before aspiration of bone
marrow, a 20 mL Luer-Lok syringe containing 5000
IU of heparin in 5 mL of normal saline was prepared
and the needlewasﬂushedwith heparin. Bonemarrow
was aspirated from a location proximal to the pending
neck osteotomy into the heparinized syringe and
transferred to a sterile universal container for transport
from the operating room to laboratory for ﬁltration.Operation of the device
BMA was concentrated via a vacuum-assisted ﬁltra-
tion approach facilitated by acoustic agitation
(Figure 1AeC). Filters were manufactured from
23 mm-thick polyethylene terephthalate to achieve
a range of uniform pore sizes (1.2e4.1 mm diameter)
and porosities (150 000e1.5 million pores/cm2) via
a track etching process (it4ip, Seneffe, Belgium).
Acoustic vibration was applied using a voice-coil
(model RM-ETNC0033K19C-2KOI; NXT Tech-
nology, Cambridge, UK). Vacuum pressure was
produced with a 6V miniature diaphragm pump
(KPV14A-6A; Koge Electronics Co., Ltd, Taipei,
Taiwan).
Following straining through a 70 mm pore-size
pre-ﬁlter (Figure 1B, ii), each BMA sample was
applied to a size-exclusion ﬁlter positioned above
a reservoir of phosphate-buffered saline (PBS)
(Figure 1B, iii). A resonant frequency wave was
passed through the PBS reservoir, agitating the
ﬁlter and BMA above it; this produced a geometric
standing waveform pattern on the aspirate ﬂuid
surface. The frequency was manually adjusted as
the remaining unconcentrated volume reduced to
maintain a standing wave and the resultant stable
cell suspension. A vacuum pressure (25 psi) was
applied from below the ﬁlter, to ﬁlter out prefer-
entially the smaller cells (erythrocytes, diameter
5e8 mm, and platelets, 1e3 mm), while retaining
the NC fraction above the ﬁlter. After ﬁltration, the
volume of aspirate remaining above the ﬁlter was
recovered as concentrated BMA for analysis
(Figure 1B, iv). Before ﬁltration, 2e5 mL of fresh
heparinized BMA was set aside as unconcentrated
control BMA.
Figure 1. Osteoprogenitor enrichment strategy. (A) BMA from the femoral canal obtained during a total hip replacement (top) and from
iliac crest (bottom). (B) BMA enrichment process. Immediately after aspiration and within the sterile ﬁeld (i), BMA is injected into the unit
(ii). After passing through a pre-ﬁlter to remove debris, the BMA is applied to a secondary ﬁlter (iii), and an acoustic wave is applied to
agitate the sample and ensure an even cell suspension. Negative pressure draws erythrocytes and platelets through the ﬁlter retaining NC
fraction via size exclusion. Enriched NCs, retained above the ﬁlter, are removed for therapeutic application (iv). (C) Concentrated bone
marrow being applied to allogeneic bone graft (allograft) before bone grafting. LCD, liquid crystal display; PCB, printed circuit board.
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Filtration was continued either to achieve a mini-
mum 4.0-fold volume reduction or until ﬂow
through the ﬁlter became laborious. Start and end
time points and starting volume and ﬁnal volume
were recorded for each sample ﬁltered.
NC count and cell viability analysis
NC counts of unconcentrated and concentrated
BMA were determined on 18 samples using Guava
EasyCyte ﬂow cytometry (Millipore, Watford, UK)
and conﬁrmed bymanual count on a hemocytometer.
Guava ViaCount Reagent (Millipore) was used to
differentiate live and dead cells, and the viable cell
count value was used in all calculations. To conﬁrm
NC enrichment relative to erythrocytes, a single
donor (female, 55 years old) was ﬁltered to 50% and
25% starting volume, and NCs were counted relative
to erythrocytes usingGuava EasyCyte ﬂow cytometry.
Statistical analysis was performed using Microsoft
Excel (Microsoft Corporation, Bellevue, WA, USA)
and SPSS Ver. 18 (IBM United Kingdom Ltd.,
Hampshire, UK).
CFU-F analysis
CFU-F assay was used as an indicator of osteopro-
genitor number present in the aspirate before andafter ﬁltration through the device and was performed
on 15 samples (Table I). After determination of viable
NC count using Guava EasyCyte ﬂow cytometry,
unconcentrated and concentrated BMA was seeded
into T25 culture ﬂasks (n ¼ 3) according to the
Friedenstein protocol for density independent growth
(25). Brieﬂy, aspirates diluted in basal media (aMEM
containing 10% fetal calf serum [FCS]) to achieve
clonal seeding densities of 1  104, and 1  105 NCs/
mL were strained to ensure a single cell suspension
and seeded at 0.2 mL/cm2. After 3 h at 37C and 5%
carbon dioxide (CO2), plates were washed twice with
PBS to remove non-adherent cells and incubated at
37C and 5% CO2 in basal media for 14 days. After
ﬁxation in 95% ethanol and staining for alkaline
phosphatase activity against Gill’s hematoxylin
nuclear counter-stain, colony number was counted,
and the CFU-F/mL value for each aspirate was
calculated taking into account the dilution factor
required to achieve clonal seeding densities. Parallel
assays of like-for-like volumes of unconcentrated and
concentrated BMA were also performed to illustrate
differences in CFU-F concentration.Flow cytometry analysis of stem cell markers
Unconcentrated and concentrated BMAs from
a single donor (male, 59 years old) were washed in
Table I. Nucleated cells and CFU-F concentrations before and after ﬁltration.a
Sex Age
Aspirated
volume (mL)
Volume fold
concentration
Pre-ﬁltration Post-ﬁltration
Viable NC
concentration
(million cells/mL)
CFU-F
concentration
(per mL BMA)
Viable NC
concentration
(million cells/mL)
CFU-F
concentration
(per mL BMA)
F 77 20 2.4 6.6 71 13.2 141
M 75 40 4.7 6.1 29 23.8 143
F 91 18 2.7 6.8 89 14.9 198
F 70 40 4.0 27.8 115 89.3 357
M 70 19 5.2 12.5 158 43.7 554
F 82 20 4.0 19.6 116 41.0 611
F 78 20 4.0 16.9 202 78.1 703
F 75 40 5.5 44.8 131 195.8 703
F 71 40 4.0 17.7 215 59.2 977
F 69 20 4.0 14.2 426 52.3 1152
M 55 40 4.0 12.1 317 40.3 1379
F 89 20 6.0 32.4 330 126.0 1418
M 52 20 4.0 18.5 368 61.6 1493
F 78 40 4.3 37.7 2108 95.4 3955
M 68 20 4.0 70.2 1032 234.1 4003
Mean 73.3 27.8 4.2 22.9 380.3 77.9 1185.8
SD 10.5 10.3 0.9 17.4 536.9 64.0 1220.9
Median 73.3 20 4 17.66 214.59 61.63 977.34
IQR 8.5 20 0.49 16.75 225.56 50.01 815.97
F, female; IQR, interquartile range; M, male; SD, standard deviation.
aConcentrations corrected for BMA dilution with heparin at time of harvest. Samples below the dotted line displayed post-ﬁltration CFU-F
concentrations above the critical therapeutic threshold of 1000 CFU-F/mL suggested by Hernigou et al. (23).
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being incubated in blocking buffer (PBS, 1% bovine
serum albumin, 10% human serum, 5% FCS) at
room temperature for 30 min. Cells were immuno-
labeled with antibodies against Stro-1 (undiluted
culture supernatant from the STRO-1 hybridoma
originally provided by Beresford, University of Bath),
CD146 (1:50, mouse monoclonal [P1H12], BD
Biosciences, San Jose, CA, USA) and CD105 (1:50,
chicken polyclonal, Abcam, Cambridge, UK) for
60 min at room temperature and then washed and
incubated with ﬂuorescently labeled secondary anti-
bodies (1:100). Labeled populations from each
sample were quantiﬁed against the relevant isotype
control using Guava EasyCyte ﬂow cytometry.Multi-lineage differentiation of concentrated and
unconcentrated populations
Following a 3.22-fold NC concentration, equal
volumes of unconcentrated and concentrated aspi-
rate from a single donor (female, 70 years old) were
seeded across culture vessels and culture expanded
for 12 days. After expansion over 14 days, cells
(which were at <80% conﬂuence) were trypsinized,
counted and reseeded in quadruplicate, at densities
consistent with the fold difference in cell number
(2.54-fold) obtained from expanded concentrated
versus unconcentrated samples, into 12-well plates
for osteogenic, adipogenic and chondrogenicdifferentiation. Control cultures were refreshed with
basal media every 3 days.Osteogenic culture
After a further 14 days in basal conditions, mono-
layer cultures of concentrated and unconcentrated
BMA were transferred to osteogenic media (aMEM
with 10% FCS, 100 mM ascorbate [ascorbic acid
2-phosphate] and 10 nM dexamethasone) for 14
days. Media were refreshed every 2e3 days.Adipogenic culture
After a further 14 days in basal conditions, monolayer
cultures of concentrated and unconcentrated BMA
were transferred to adipogenic media consisting of
basal cell culture media containing additional 2 g/L
D-glucose and 0.5 mM 3-isobutyl-1-methylxanthine,
1 mM dexamethasone, 1% ITS solution (equal to
10 mg/mL insulin; Sigma-Aldrich, St Louis, MO,
USA) and 100 mM indomethacin for 3 days followed
by 1 day in basal cell culture media containing 1%
ITS solution. Both cycles were repeated for 28 days.Chondrogenic culture
Monolayer expanded cells were seeded at high
density (unconcentrated BMA 1.475  106 cells/mL;
concentrated BMA 3.75  106 cells/mL) in 20 mL
246 J. I. Dawson et al.volumes at the center of each well and, after 30 min
incubation to allow cell adhesion, cultured in chon-
drogenic media (serum-free aMEM supplemented
with 10 ng/mL transforming growth factor-b3,
10 nM dexamethasone, 100 mM ascorbate, and
10 mL/mL 100  ITS solution) for 21 days. Media
were refreshed every 2e3 days.Histologic staining and quantiﬁcation of differentiated
cultures
Osteogenic differentiation was determined using
alkaline phosphatase histochemical staining, demon-
strated with Naphthol AS-MX Phosphate and Fast
Violet B Salt (both Sigma-Aldrich). Relative alkaline
phosphatase staining intensity was quantiﬁed using
CellProﬁler image analysis software (Broad Institute,
Cambridge, MA, USA). Brieﬂy, low magniﬁcation
(25) brightﬁeld color images were taken in quadru-
plicate at regular points across each well. Positive
staining was identiﬁed from background using the
CellProﬁler UnmixColors module. Staining intensity
was normalized by setting the minimum intensity of
each image to zero and rescaling stain intensities rela-
tive to the maximum intensity across all images using
the CellProﬁler RescaleIntensity module. Accurate
representation of each image was conﬁrmed by eye
before the mean intensity of each image was measured
using the CellProﬁler MeasureIntensity module.
Adipogenic differentiation was identiﬁed by
adipocyte accumulation of lipid droplets observed
under light microscopy using a Zeiss microscope
(Carl Zeiss, Cambridge, UK) and after staining for
lipid with oil red O histochemistry. Brieﬂy, cells were
ﬁxed in Baker’s formal calcium, rinsed in 60% iso-
propanol, and stained using double-ﬁltered oil red O
solution. After imaging, oil red O staining was
leached from the cells in 100% isopropanol, and
absorbance was measured via spectrophotometry.
Chondrogenic differentiation was determined by
staining for proteoglycan with alcian blue. After
imaging, alcian blue staining was leached using 0.5%
Triton X-100, and absorbance was measured via
spectrophotometry.Cell seeding onto decellularized human trabecular bone
graft material
Decellularized human trabecular bone allograft was
prepared as previously described using sequential
hydrogen peroxide and PBS washes (26). BMA from
the iliac crest of a single donor (male, 39 years old)
was ﬁltered through the device to achieve a fold
reduction in volume of 7.4. The relatively high
fold volume reduction was achieved to facilitate
observation of effects over the high variationcharacteristically observed in studies of three-
dimensional seeding efﬁciency. A corresponding 7.2-
fold increase in the concentration of NCs was
conﬁrmed via ﬂow cytometry. Equal volumes of
unconcentrated BMA and concentrated BMA were
applied to bone graft to assess the effect of concen-
tration of BMA on seeding. Two further preparations
were applied to bone as controls: (i) a 7.4-fold
reduced volume of concentrated BMA to normalize
to unconcentrated BMA by NC number and (ii)
a 7.4-fold reduced volume of concentrated BMA
rediluted in PBS to normalize to unconcentrated
BMA by both volume and NC number. Aspirates
were applied so as to immerse approximately 5 mm3
pieces of decellularized human trabecular bone.
After an 18 h incubation under gentle agitation,
excess BMA was removed, and samples were washed
twice with PBS before being reimmersed in aMEM
with 10% FCS. Samples were cultured for a further
48 h before cell quantiﬁcation and viability analysis.WST-1 assay for relative quantiﬁcation of cell seeding
After seeding and a 48-h culture period, the extent of
cell seeding and growth on decellularized human
trabecular bone matrix was assessed via the colori-
metric WST-1 assay for metabolic activity (Cat. No.
11644807001; Roche, West Sussex, UK). Seeded
matrices were washed twice with PBS, re-immersed
in 9% WST-1 reagent and transferred to an incu-
bator. After 2 h, the absorbance was read at 450 nm
on an ELx800 microplate reader (BioTek Instru-
ments, Winooski, VT, USA).Cell viability and imaging
Before ﬁxation, cell cultures were incubated for
45min (37C and 5%CO2) in the presence of aMEM
containing 10 mg/mLCellTracker Green and 5 mg/mL
Ethidium Homodimer-1 (both Invitrogen, Carlsbad,
CA, USA) to label viable and necrotic cells. Cells
were incubated in fresh aMEM for a further 45 min
before ﬁxing in 95% ethanol for 15 min. Fluorescent
imaging was conducted on a Zeiss Axiovert 200
inverted microscope equipped with an AxioCam
MRm monochrome camera and an X-Cite 120 ﬂuo-
rescence light source (all Carl Zeiss, Cambridge, UK).Results
Femoral BMA sampled from 15 patients from elderly
cohort was concentrated 4-fold with corresponding
enrichment of osteoprogenitors
Fifteen samples were successfully ﬁltered, after
which further analysis was performed. Samples were
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a mean age of 73 years (range, 52e91 years). All
samples were analyzed for NC number and viability
and cultured for CFU-F analysis (Table I). No
signiﬁcant difference in ﬁltration time, NC count or
colony-forming efﬁciency was observed between the
sexes or across the age range of this elderly cohort
(data not shown).
The 15 freshly obtained samples of BMA were
ﬁltered to achieve a 2-fold to 6-fold reduction in
volume (mean ¼ 4.2) with an average ﬁltration
time of 18.23 min. Eight samples were ﬁltered to
achieve the target 4-fold volume reduction, and ﬁve
samples were ﬁltered to achieve >4-fold volume
reduction. Counts of viable cells after a 2-fold and
then 4-fold reduction in volume revealed a corre-
sponding increase in the concentration of NCs in
the concentrated aspirate relative to both volume
and erythrocyte concentration (Figure 2A). Flow
cytometry analysis of commonly used markers for
osteoprogenitors revealed enrichment of these cells
in the concentrated BMA volume (Figure 2B), and
an increase in the concentration of CFU-F was
observed via colony-forming efﬁciency analysis
(Figure 2C). A viable NC concentration of mean 3.4Figure 2. Osteoprogenitor enrichment of BMA. (A) After ﬁltration to
concentration of total NCs relative to erythrocytes/ RBCs was observed.
analysis of BMA from a different patient (unconcentrated NC count
osteoprogenitors revealed a corresponding enrichment in concentrated
volumes of unconcentrated and concentrated BMA were cultured for
phosphatase. In this case, a 3.7-fold increase in CFU-F was observed. (D
was observed in relation to the volume ﬁltered. (E) Although cell viabil
retention of NCs was observed when samples were ﬁltered to achieve >
CFU-F relative to the aspirate volume ﬁltered was observed.(0.69) was observed after 4-fold volume reduction
(Figure 2D) indicating 82% (16.93) of NCs were
recovered after ﬁltration (Figure 2E). An equivalent
CFU-F concentration of 3.9 (0.83) was observed
(Figure 2F). When BMA was ﬁltered to achieve
>4-fold volume reduction, a decline in NC recovery
(mean ¼ 69.1%  10.6) was observed (Figure 2E).Concentrated BMA displayed increased osteogenesis and
chondrogenesis and reduced adipogenesis in vitro
After a 3.22-fold concentration of NCs via acoustic-
mediated ﬁltration, concentrated and unconcentrated
BMAs from a single patient were seeded at an equal
volume and cells were expanded before being trans-
ferred to differentiation conditions to assess the effect
of cell concentration on the response to multilineage
induction. Cells from concentrated BMA seeded onto
tissue culture plastic at an equal volume to uncon-
centrated BMA displayed signiﬁcantly higher alkaline
phosphatase activity (P< 0.05) in both osteogenic and
basal conditions (Figure 3A). When cells obtained
from concentrated versus unconcentrated BMA were
seeded at equivalent cell concentrations into chon-
drogenic high-density culture conditions, signiﬁcantlyachieve 2-fold and 4-fold volume reductions, a corresponding
Error bars:  standard deviation of replicates. (B) Flow cytometry
¼ 14.5  106/mL) immunolabeled for markers associated with
samples. Error bars:  standard deviation of replicates. (C) Equal
14 days, and colonies were counted after staining for alkaline
) Across the 15 samples, a corresponding enrichment of total NCs
ity was maintained during ﬁltration, a reduction in the percentage
4-fold reduction in volume. (F) A corresponding enrichment of
Figure 3. Multilineage induction of human bone marrow stromal cell cultures derived from concentrated versus unconcentrated BMA.
Following a 3.22-fold concentration, aspirates were seeded at equal volumes and cells expanded before being transferred to differentiation
conditions. Enhanced osteogenesis (A) (alkaline phosphatase activity; *P < 0.05) and chondrogenesis (B) (proteoglycan; ***P < 0.001) but
reduced adipogenesis (C) (lipid; ***P < 0.001) were observed in concentrated samples relative to unconcentrated samples. (abs,
absorbance.)
248 J. I. Dawson et al.higher proteoglycan synthesis (P < 0.001) was
observed in concentrated samples with negligible
alcian blue staining for proteoglycan being observed in
cultures derived from and seeded at densities equiva-
lent to unconcentrated BMA (Figure 3B). In contrast,
under adipogenic conditions, higher density seeding
facilitated by BMA concentration was observed to
reduce signiﬁcantly (P < 0.001) the response to adi-
pogenic induction compared with unconcentrated
BMA (Figure 3C).Osteoprogenitor enrichment of BMA improves
cell-seeding efﬁciency onto bone graft
To assess the effect of concentration of BMA on the
seeding efﬁciency of adherent cells onto allogeneic
bone graft, 25 mL of freshly obtained aspirate was
ﬁltered to achieve a 7.4-fold reduction in volume.
Total NC counts revealed a 7.2-fold concentration
of NCs with 97.8% viability corresponding to a
95.1% viable NC retention efﬁciency. Equal volumes
of concentrated (Conc.vol.) and unconcentrated
(Unconc.) BMA were seeded onto decellularized
human trabecular bone and, after culture, assessed for
relative seeding efﬁciency via imaging of viable cells
and an assay for relativemetabolic activity (Figure 4A).
To control for the various possible factors affecting
seeding efﬁciency, two further control samples wereprepared: concentrated BMA was added at 7.2-fold
reduced volume to normalize for cell number and
assess for the effect of concentration alone (Conc.cell),
and a 7.2-fold reduced volume of concentrated BMA
was re-diluted in PBS to normalize for volume and cell
number and assess for the effect of NC concentration
relative to erythrocytes alone (Conc.cellþvol.). In all
cases, concentrated BMA demonstrated signiﬁcantly
higher seeding efﬁciency than the unconcentrated
control (Figure 4B,C). Conc.vol. resulted in the
highest seeding reﬂecting the increased number of
NCs present in these samples; however, concentra-
tion resulted in signiﬁcantly higher seeding even
when normalized for cell number (Conc.cell and
Conc.cellþvol.). The fact that the increase in seeding
efﬁciency was not lost when concentrated BMA was
re-diluted (Conc.cellþvol.) indicates that the enhanced
seeding observed in the samples normalized to the
control by cell number can be attributed to concen-
tration of NC number relative to erythrocytes.Discussion
In the current study we assessed the potential of an
acoustic wave-facilitated ﬁltration technique to
enrich BMA from an elderly cohort for the NC
population, and tested the hypothesis that such cell
enrichment enhances the regenerative efﬁcacy of
Figure 4. Enhanced cell seeding efﬁciency via BMA enrichment. BMA was concentrated and seeded, at equal volumes, onto allograft
(Conc.vol.) to compare seeding efﬁciency relative to unconcentrated controls (Unconc.). In addition, concentrated BMA was normalized to
the control by NC number (Conc.cell) or normalized by cell number and volume by redilution (Conc.cellþvol.) to assess the effect of
concentration apart from cell number and concentration relative to erythrocytes (A). In all cases, seeding efﬁciency is signiﬁcantly higher
(***P < 0.001) when BMA is concentrated, as observed via WST-1 assays for gross metabolic activity (B) and CMFDA-1 staining (C).
(Scale bars ¼ 200 mm.) (abs, absorbance.)
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reduction in BMA from the femoral canal of a cohort
of elderly patients. After ﬁltering the sample to ach-
ieve a 4-fold reduction in volume, a corresponding
3.4-fold enrichment of viable NCs and a 3.9-fold
enrichment of CFU-F was observed (difference not
signiﬁcant), demonstrating this device to be effective
in the intended function of osteoprogenitor enrich-
ment. The average ﬁltration time of 18 minutes
proved the viability and practicality for intraoperative
clinical application of the device.
There was a wide variation of CFU-F/mL from
the aspirated marrow of this cohort of patients
(29-2108 CFU-F/mL), although a wide range was
also seen in a young cohort previously tested
(710e1440 CFU-F/mL) (JN Ridgway, SJ Curran,
unpublished observations, 2010). These values are
also consistent with a recent study comparing CFU-F
numbers obtained from the iliac crest and the femoral
canal (27). Dilution of marrow with peripheral blood
during sampling is also likely to account for some
variability (28,29). This may explain the variable
outcomes seen in clinical practice and account for thelow CFU-F counts after concentration by centrifu-
gation in the seven cases of non-union in the series by
Hernigou et al. (23). Initial osteoprogenitor number
in BMA from our cohort of elderly patients had
a mean of 380 CFU-F/mL signiﬁcantly lower than
the therapeutic threshold of 1000 CFU-F/mL sug-
gested by Hernigou et al. (23).
A phenomenon of age-related decline in CFU-F
number has been suggested by some authors (16,30),
although other studies have demonstrated mainte-
nance of osteoprogenitor number and function with
aging, including in osteoarthritic and osteoporotic
bone (31e33). Nevertheless, the clinical indication
for bone tissue engineering technology is most
applicable to elderly patients, and the low CFU-F
number found in this cohort of elderly patients
highlights the pressing need for cell enrichment
strategies in clinical practice. Enrichment of CFU-F
by 3.7-fold over all samples ﬁltered increased the
mean value in concentrated aspirate to 1185 CFU-
F/mL. There was a close correspondence between
volume reduction and concentration of viable NC
count relative to both total volume and erythrocyte
250 J. I. Dawson et al.number indicating good speciﬁcity of ﬁltration.
Additionally, enriched aspirate contained signiﬁ-
cantly higher concentrations per milliliter aspirate of
cells expressing three widely used osteoprogenitor
cell markers.
Following signiﬁcant previous clinical and
pre-clinical studies indicating the importance of
osteoprogenitor concentration for bone repair
(10,19,20,22,23,34), we designed two in vitro exper-
iments to probe the regenerative signiﬁcance of BMA
cell concentration by assessing the effect of cell
concentration on skeletal differentiation and seeding
efﬁciency. After culture in osteogenic, chondrogenic
and adipogenic differentiation conditions, an
enhanced osteogenic and chondrogenic response but
reduced adipogenic differentiation was observed in
concentrated populations compared with populations
derived from unconcentrated BMA. These signiﬁcant
differences, which reﬂect differences of initial cell-
seeding density between treatments, were observed
despite a relatively small fold difference in cell number
(2.54) after the initial phase of expansion. These
results underline the importance of cell concentration
for the outcome of skeletal regeneration strategies.
The importance of higher cell density for chondro-
genic differentiation is well established and provides
the rationale for micro-mass culture approaches to
chondrogenic differentiation (35e37); however, the
inﬂuence of initial cell-seeding density on osteogenic
and adipogenic differentiation remains controversial
(38e42). The reduced adipogenic responsiveness
observed in this study may be a function of the
increased levels of alkaline phosphatase activity, indi-
cating early osteogenesis, observed in basal cultures of
concentrated BMA.
The seeding of cells onto three-dimensional scaf-
folds and matrices is an important step in many tissue
engineering approaches. Several recent studies have
made use of allograft or allograft substitute materials
seededwithBMA (11,12,20,43), so the demonstration
that cells enriched by the acoustic ﬁltration method
adhere in greater numbers onto allograft after enrich-
ment is highly signiﬁcant. In the current study, we have
demonstrated a signiﬁcantly greater enhancement of
seeding efﬁciency in concentrated BMA compared
with unconcentrated BMA. We have shown that the
effect is not only a function of higher NC number
within a given plasma volume, although this is itself an
important observation in a technique where volume is
often a limiting factor, but also that seeding efﬁcacy is
improved critically as a function of reduced erythro-
cytes. This ﬁnding is consistent with a previous study
demonstrating the positive effect of erythrocyte lysis on
CFU-F growth (28) and indicates that even in a situa-
tion where cell number is limiting, ﬁltration of eryth-
rocytes is itself beneﬁcial for tissue engineeringstrategies using BMA. The negative impact of eryth-
rocyte number on seeding efﬁciency may offer an
insight into why concentration of osteoprogenitors is of
regenerative signiﬁcance independent of total number
of osteoprogenitors delivered.
The current study provides evidence for the
importance of BMA NC concentration for cell
differentiation and seeding of scaffolds using an
approach designed to be applicable intraoperatively.
Substantial heterogeneity remains within this fraction
with the CFU-F population constituting, in this
cohort, a mean of only 0.012% (0.013%) of total
NCs. Furthermore, well-documented functional
heterogeneity exists within the CFU-F fraction itself
(44,45). There is thus considerable scope for further
enrichment of osteoprogenitors, and a large body of
research is devoted to developing approaches to
achieving this. It should be noted however, that while
this and previous studies (10,20,22,23,28) have
indicated the importance of CFU-F concentration
for regenerative outcome, the increments of beneﬁt
derived from further enrichment steps are yet to be
deﬁned experimentally in the current context of bone
grafting, and the relationship of concentration and
efﬁcacy is not necessarily straightforward (46,47).
Further work is therefore required to conﬁrm the
beneﬁts of further enrichment in balance with the
inherent risks of increasingly involved processes.
In conclusion, given the demographics of an
increasing and aging population, there is a pressing
need for the translation of efﬁcient reconstructive
strategies suitable for therapeutic use. Current
successful intraoperative strategies for administration
of concentrated BMA exploit the available time
interval between initial marrow aspiration at the start
of the operation and implantation toward the end of
the procedure; this allows approximately 20e30
minutes to prepare the aspirate. Gradient centrifu-
gation approaches allow preparation of BMA within
this time frame and are the current choice for intra-
operative concentration, with several successful sys-
tems in routine use (MarrowStim [Biomet, Warsaw,
IN, USA)], Res-Q [ThermoGenesis, Rancho Cor-
dova, CA, USA], SmartPReP 2 [Harvest Tech-
nologies, Plymouth, MA, USA], Biosafe [Sepax
Technologies, Newark, DE, USA]). These tech-
niques have shown proven beneﬁts in vitro (48,49), in
animal models (50,51) and in a variety of different
clinical indications including osseous defects,
osteonecrosis, osteoarthritis and peripheral vascular
disease (11,20,23,43,52,53). However, despite the
success of this technique, centrifugation approaches
entail considerable capital equipment expenditure
and, due to their size and lack of sterility, preclude
BMA concentration within the surgical ﬁeld risking
infection as well as donor cross-contamination
Enhancing the osteogenic efﬁcacy of human bone marrow aspirate 251(24,28). We have presented an efﬁcient and inex-
pensive solution to cell enrichment amenable for
development toward a single-use device and able to
be applied intraoperatively within the sterile ﬁeld,
offering considerable potential for clinical beneﬁt.
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